First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2

por Catlett, Ian M., Aras, Urvi, Hansen, Lars, Liu, Yali, Bei, Di, Girgis, Ihab G., Murthy, Bindu
Publicado 2022

Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects

por Jing, Shan, Lin, Yang, Dockens, Randy, Marchisin, David, He, Bing, Girgis, Ihab G., Chimalakonda, Anjaneya, Murthy, Bindu, Aras, Urvi
Publicado 2023

Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)

por Sangro, Bruno, Yau, Thomas, El‐Khoueiry, Anthony B., Kudo, Masatoshi, Shen, Yun, Tschaika, Marina, Roy, Amit, Feng, Yan, Gao, Ling, Aras, Urvi
Publicado 2023

Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects

por Chimalakonda, Anjaneya, Singhal, Shalabh, Darbenzio, Raymond, Dockens, Randy, Marchisin, David, Banerjee, Subhashis, Girgis, Ihab G., Throup, John, He, Bing, Aras, Urvi, Murthy, Bindu
Publicado 2022